Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 48.26 Billion KRW | 6.6% |
| 2022 | 45.27 Billion KRW | 58.04% |
| 2021 | 28.64 Billion KRW | 7.65% |
| 2020 | 26.61 Billion KRW | -13.92% |
| 2019 | 30.91 Billion KRW | -2.39% |
| 2018 | 31.67 Billion KRW | 13.67% |
| 2017 | 27.86 Billion KRW | 42.79% |
| 2016 | 19.51 Billion KRW | -10.16% |
| 2015 | 21.72 Billion KRW | 18.21% |
| 2014 | 18.37 Billion KRW | 50.46% |
| 2013 | 12.21 Billion KRW | -25.44% |
| 2012 | 16.37 Billion KRW | -18.95% |
| 2011 | 20.2 Billion KRW | 19.98% |
| 2010 | 16.84 Billion KRW | 18.62% |
| 2009 | 14.19 Billion KRW | 60.01% |
| 2008 | 8.87 Billion KRW | 59.17% |
| 2007 | 5.57 Billion KRW | 41.13% |
| 2006 | 3.95 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 5.25 Billion KRW | 182.24% |
| 2024 Q1 | 19.18 Billion KRW | 640.79% |
| 2024 Q2 | -6.38 Billion KRW | -133.28% |
| 2023 Q4 | 2.59 Billion KRW | -84.63% |
| 2023 Q3 | 16.84 Billion KRW | 17.35% |
| 2023 Q2 | 14.35 Billion KRW | -0.73% |
| 2023 Q1 | 14.46 Billion KRW | 403.05% |
| 2023 FY | 48.26 Billion KRW | 6.6% |
| 2022 FY | 45.27 Billion KRW | 58.04% |
| 2022 Q3 | 23.85 Billion KRW | 62.04% |
| 2022 Q1 | 11.46 Billion KRW | 450.33% |
| 2022 Q2 | 14.72 Billion KRW | 28.4% |
| 2022 Q4 | -4.77 Billion KRW | -120.0% |
| 2021 Q3 | 10.8 Billion KRW | 63.87% |
| 2021 Q4 | 2.08 Billion KRW | -80.71% |
| 2021 Q1 | 9.16 Billion KRW | 242.06% |
| 2021 FY | 28.64 Billion KRW | 7.65% |
| 2021 Q2 | 6.59 Billion KRW | -28.1% |
| 2020 Q1 | 11.66 Billion KRW | 90.24% |
| 2020 Q2 | 4.36 Billion KRW | -62.55% |
| 2020 Q3 | 7.89 Billion KRW | 80.77% |
| 2020 Q4 | 2.68 Billion KRW | -66.06% |
| 2020 FY | 26.61 Billion KRW | -13.92% |
| 2019 Q1 | 9.28 Billion KRW | 17.0% |
| 2019 Q3 | 8.96 Billion KRW | 37.27% |
| 2019 FY | 30.91 Billion KRW | -2.39% |
| 2019 Q4 | 6.13 Billion KRW | -31.62% |
| 2019 Q2 | 6.53 Billion KRW | -29.63% |
| 2018 FY | 31.67 Billion KRW | 13.67% |
| 2018 Q4 | 7.93 Billion KRW | 8.76% |
| 2018 Q1 | 8.51 Billion KRW | 52.22% |
| 2018 Q2 | 7.92 Billion KRW | -6.84% |
| 2018 Q3 | 7.29 Billion KRW | -8.0% |
| 2017 Q1 | 4.89 Billion KRW | -22.94% |
| 2017 Q3 | 10.67 Billion KRW | 59.54% |
| 2017 Q2 | 6.69 Billion KRW | 36.61% |
| 2017 FY | 27.86 Billion KRW | 42.79% |
| 2017 Q4 | 5.59 Billion KRW | -47.64% |
| 2016 Q2 | 1.72 Billion KRW | -75.52% |
| 2016 Q4 | 6.35 Billion KRW | 44.36% |
| 2016 Q3 | 4.4 Billion KRW | 155.92% |
| 2016 FY | 19.51 Billion KRW | -10.16% |
| 2016 Q1 | 7.02 Billion KRW | 0.0% |
| 2015 FY | 21.72 Billion KRW | 18.21% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 4.94 Billion KRW | 20.14% |
| 2015 Q2 | 4.11 Billion KRW | -33.92% |
| 2015 Q1 | 6.22 Billion KRW | 31.32% |
| 2014 Q4 | 4.74 Billion KRW | -10.89% |
| 2014 FY | 18.37 Billion KRW | 50.46% |
| 2014 Q1 | 5.34 Billion KRW | 83.62% |
| 2014 Q3 | 5.32 Billion KRW | 79.43% |
| 2014 Q2 | 2.96 Billion KRW | -44.57% |
| 2013 Q4 | 2.91 Billion KRW | 30.94% |
| 2013 FY | 12.21 Billion KRW | -25.44% |
| 2013 Q1 | 4.11 Billion KRW | 19.98% |
| 2013 Q2 | 2.96 Billion KRW | -27.92% |
| 2013 Q3 | 2.22 Billion KRW | -24.93% |
| 2012 Q3 | 3.28 Billion KRW | -17.02% |
| 2012 Q4 | 3.42 Billion KRW | 4.34% |
| 2012 FY | 16.37 Billion KRW | -18.95% |
| 2012 Q1 | 6.03 Billion KRW | 0.0% |
| 2012 Q2 | 3.95 Billion KRW | -34.4% |
| 2011 Q3 | 6.07 Billion KRW | -6.27% |
| 2011 Q2 | 6.48 Billion KRW | 7.9% |
| 2011 FY | 20.2 Billion KRW | 19.98% |
| 2011 Q1 | 6 Billion KRW | 63.21% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 4.85 Billion KRW | 50.43% |
| 2010 Q1 | 3.22 Billion KRW | 127.21% |
| 2010 Q4 | 3.68 Billion KRW | -27.64% |
| 2010 Q3 | 5.08 Billion KRW | 4.84% |
| 2010 FY | 16.84 Billion KRW | 18.62% |
| 2009 Q4 | 1.41 Billion KRW | -55.93% |
| 2009 FY | 14.19 Billion KRW | 60.01% |
| 2009 Q1 | 5.48 Billion KRW | 463.62% |
| 2009 Q2 | 4.07 Billion KRW | -25.75% |
| 2009 Q3 | 3.22 Billion KRW | -20.91% |
| 2008 Q4 | 973.25 Million KRW | -57.74% |
| 2008 Q2 | 2.86 Billion KRW | 4.77% |
| 2008 Q1 | 2.73 Billion KRW | 0.0% |
| 2008 FY | 8.87 Billion KRW | 59.17% |
| 2008 Q3 | 2.3 Billion KRW | -19.58% |
| 2007 Q2 | 1.96 Billion KRW | 0.0% |
| 2007 Q3 | 1.65 Billion KRW | -15.76% |
| 2007 FY | 5.57 Billion KRW | 41.13% |
| 2006 FY | 3.95 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 772.084% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 16.775% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 180.994% |
| HANDOK Inc. | -28.79 Billion KRW | 267.59% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 673.507% |
| Yuhan Corporation | 93.5 Billion KRW | 48.388% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -333.912% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 294.509% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 66.996% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -1275.523% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 2025.528% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 2427.089% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 1166.596% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -116.103% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 772.084% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 330.466% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -1246.824% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 140.806% |
| JW Holdings Corporation | 19.02 Billion KRW | -153.658% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 161.146% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 77.291% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -30.415% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 184.189% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -688.363% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -2801.146% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -864.319% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 772.084% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -30.559% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 56.717% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -30.415% |
| Yuhan Corporation | 93.5 Billion KRW | 48.388% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 397.0% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 1345.289% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -688.69% |
| JW Pharmaceutical Corporation | 37 Billion KRW | -30.415% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -155.275% |
| CKD Bio Corp. | -24.19 Billion KRW | 299.49% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -101.789% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -75.892% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -62.092% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 184.189% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | -2.668% |
| Boryung Corporation | 40.2 Billion KRW | -20.046% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 254.045% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 2025.528% |
| JW Lifescience Corporation | 28.14 Billion KRW | -71.482% |